Objectives. To compare clinical outcomes and treatment patterns among patients with moderate vs severe RA following biologic DMARD initiation.
Introduction
Improvements in clinical disease activity, physical function, radiographic outcomes and rates of joint surgery in RA have been documented following the initial introduction of anti-TNF biologics in 1998 [16] . Aggressive treatment with both biologic and non-biologic DMARDs has made remission feasible for many patients with RA, and treat-to-target (T2T) principles recommend pursuing remission or low disease activity (LDA) for most patients with RA [7, 8] .
Clinical trial results have shown that in patients with both early and long-standing RA, the level of disease activity achieved following initiation of anti-TNF therapy is correlated with disease activity at the time of initiation [9, 10] . Therefore, achievement of aggressive therapeutic targets may not be as readily achieved in patients with severe disease compared with those with moderate disease at initiation. In addition, physicians and patients may be reluctant to change from a therapy that is perceived to be working, even if they have not achieved targets such as LDA, particularly if a meaningful therapeutic response has been achieved [11, 12] . Presently there is limited realworld evidence comparing treatment patterns and clinical outcomes in RA patients who initiate biologic therapy at different levels of disease activity.
The current study used data from a large US-based patient registry to assess real-world treatment patterns and outcomes among patients with RA over nearly 12 years. The specific objectives of the current study were to assess whether initiating biologics among RA patients with moderate disease activity results in better clinical outcomes compared with patients with more severe disease activity and to assess potential differences in treatment patterns among patients in these groups following biologics initiation.
Methods

Study design and patient selection
We performed a retrospective analysis (from October 2001 through March 2013) of data from Corrona, a large US RA patient registry [13] . As of 30 May 2015, the database included 40 989 patients with RA. Corrona collects data from routine office visits (typically at 3À4 month intervals) at both academic and community rheumatology practices. Assessments include common measures of disease activity, physical functioning and medication use. The Corrona protocol was approved by the Western Institutional Review Board and all patients enrolled in Corrona provided written informed consent. All data were de-identified to protect patient confidentiality. No additional ethical approval was required for this study.
For the current study, biologics-naive RA patients who initiated a biologic DMARD and had 1 or 2 years of followup (visit within 915 months of initiation and 2127 months of initiation, respectively) and moderate to severe disease activity at initiation [Clinical Disease Activity Index (CDAI) >10] were selected for analysis [14] . Patient sociodemographic and clinical characteristics (age, gender, work status, BMI, RA duration and co-morbidities) were assessed at the time of biologics initiation; disease activity (CDAI), functional status [modified HAQ (mHAQ)] and patterns of drug use were assessed at initiation and at each subsequent visit for the duration of follow-up.
Study outcomes and statistical analysis
For analysis, patients were stratified according to baseline disease activity as moderate (CDAI >10422) vs severe (CDAI >22) disease activity [14] . Changes in clinical outcomes and treatment patterns were assessed over the follow-up period. Clinical outcomes included the percentage of patients in remission (CDAI 42.8) or LDA (CDAI 410) at 1 and 2 years, mean change in CDAI and mHAQ from baseline (first biologic drug initiation) at 1 and 2 years, mean cumulative CDAI and mHAQ over 1 and 2 years (area under the curve standardized by the length of follow-up computed for each patient) and swollen and tender joint counts. The minimal clinically important difference (MCID) for CDAI (defined as 56 for those with moderate disease activity and 511 for those with severe disease activity), mHAQ (change 50.25), pain (change >10) and fatigue (change >10) were also evaluated [1518] . Treatment patterns assessed included the percentage of patients who remained on their original biologic drug at 1 and 2 years, the percentage of patients who switched biologics (and the mean number of switches in 1 and 2 years) and the percentage of patients who discontinued biologics use during the study period (1 or 2 years).
Descriptive statistics were used to compare baseline characteristics and outcomes at years 1 and 2 between the moderate and severe disease groups. Differences between groups in binary outcomes (such as remission and LDA) were compared using Fisher's exact test; continuous outcomes (mean cumulative CDAI, change in CDAI and in mHAQ) were compared using MannWhitneyWilcoxon rank tests. Test statistics and P-values were estimated using Monte Carlo permutation tests.
A mixed-effects linear regression model was used to estimate the time trends of CDAI and mHAQ by disease activity group (moderate vs severe) with the patient as a random effect. This model included data from all follow-up visits during the 1 or 2 year study period. We first used local regression (lowess) curves to inform the functional form (linear vs non-linear) of the trends in CDAI and mHAQ over time. Based on the observed trends, a model containing linear, quadratic and cubic terms in time was developed to fit the data. Sensitivity analyses with varying model parameters were performed to confirm the overall trends and to optimize the model fit. Model estimates were plotted at monthly intervals over the course of follow-up. Our a priori analysis plan called for frequency matching on age, gender, RA duration and/or year of initiation if not in balance between the two groups; however, there were no significant differences in these factors and matching was not necessary.
Results
Baseline sociodemographic and clinical characteristics
A total of 1596 patients who met the study inclusion criteria (779 with moderate disease activity and 817 with severe disease activity) initiated biologic therapy and had 51 year of follow-up; 1269 patients (634 moderate and 635 severe) had 52 years of follow-up. Sociodemographic characteristics and medical history were similar among patients with moderate vs severe disease activity at baseline, except that higher percentages of patients with moderate disease activity were working full time and fewer were disabled compared with the patients with severe disease activity ( Table 1) . As expected, baseline measures of disease activity and physical functioning were significantly different between the two cohorts, consistent with the classification according to moderate vs severe disease (Table 2 ; all P < 0.0001). No differences were observed in the median disease duration, year of biologics initiation or percentage of patients using combination therapy. Approximately 85% of patients received non-biologic DMARDs at the time of biologics initiation, with >70% of all patients receiving MTX.
Clinical outcomes at years 1 and 2
Patients with severe disease activity at baseline experienced a greater magnitude of improvement in overall disease activity and physical function following biologics initiation compared with those with moderate disease activity (Table 3 ). The mean change from baseline in CDAI was À18.9 vs À6.0 at year 1 and À21.0 vs À7.1 at year 2; the cumulative CDAI was 20.4 (S.D. 9.7) vs 11.7 (S.D. 6.5) at year 1 and 17.5 (S.D. 9.5) vs 10.7 (S.D. 6.4) at year 2 (P < 0.0001, all comparisons). The mean change in mHAQ score from baseline was À0.2 vs À0.1 (P < 0.0001) at year 1 and À0.2 vs À0.1 (P = 0.0013) at year 2; the cumulative mHAQ was 0.52 (S.D. 0.42) vs 0.36 (S.D. 0.38) at year 1 and 0.48 (S.D. 0.40) vs 0.34 (S.D. 0.39) at year 2 (P < 0.0001, both comparisons). In addition, the percentage of patients achieving a minimum clinically important improvement in CDAI, mHAQ and pain was higher among severe disease activity patients. However, swollen and tender joint counts were lower among moderate disease activity patients at years 1 and 2. In addition, greater proportions of patients with moderate disease activity vs severe disease activity achieved either remission [22.7 vs 15.8% (P = 0.0003) at year 1 and 25.9 vs 20.9% (P = 0.0396) at year 2] or LDA (60.1 vs 41.2% at year 1 and 66.7 vs 49.4% at year 2; both P < 0.0001) following biologics initiation. Results from the regression analysis confirmed this trend; patients with moderate disease activity at biologics initiation achieved and sustained significantly lower CDAI scores over the entire course of follow-up than did patients with severe disease activity ( Fig. 1A and B) . Similar results were observed for mHAQ ( Fig. 1C and D) . The plots show apparent moderate increases in CDAI and mHAQ following the initial treatment responses; however, the results of sensitivity analyses (data not shown) indicated these trends to be functions of the parametric model fit rather than actual increases in disease activity and functional disability.
Treatment patterns
Overall, patterns of biologic drug use over the course of follow-up were similar among patients with moderate and high baseline disease activity (Table 3) . A majority of patients in each cohort remained on the original biologic drug (>70% at year 1 and >62% at year 2). Approximately 1112% of patients switched biologics during year 1 and 1920% switched biologics during year 2. Among patients who switched biologics, the majority had one change in biologic therapy (>90% at year 1 and >84% at year 2). Approximately 1718% of patients discontinued biologic therapy over the course of followup, with the majority of these patients discontinuing during the first year.
Discussion
In this real-world study of RA patients who initiated biologic therapy as part of their routine clinical care, biologic treatment was associated with improvements in disease activity and physical function that were sustained over the course of 2 years of follow-up. Patients with severe disease activity generally experienced greater magnitudes of improvement overall than those with moderate disease activity. This finding was expected since patients with severe disease activity have a higher mean disease activity state at baseline, while a floor effect may occur among patients in the moderate disease activity group who have lower mean disease activity and are already closer to a better disease activity state [10] . For patients with moderate disease, mean improvements in the CDAI (6.0 and 7.1 at years 1 and 2, respectively) met or exceeded the MCID of 6 defined by Curtis et al. [15] . For patients with severe disease, mean improvements in the CDAI (18.9 and 20.0 at years 1 and 2) exceeded the MCID of 12.
A similar trend was observed for improvement in physical function as measured by the mHAQ. In contrast, patients who initiated biologic therapy with moderate disease activity were significantly more likely to achieve treatment targets; at 1 year, $30% more patients who initiated with moderate disease activity vs severe disease activity were in remission or LDA. These results raise the possibility that there might be a greater likelihood of achieving aggressive treatment targets such as LDA or remission if biologic therapy is initiated before patients reach higher levels of disease activity. Our results are also consistent with previous studies showing that patients with lower disease activity early in the course of DMARD treatment are more likely to achieve remission across a variety of DMARD therapies. For example, an analysis of pooled data from six clinical trials of MTX and anti-TNF therapy (both alone and in combination) showed that lower baseline disease activity (as measured by the CDAI, Simplified Disease Activity Index or 28-joint DAS) was associated with a significantly greater probability of achieving remission at 1 year of treatment, regardless of the magnitude of improvement [9] . In addition, a systematic review of studies that analysed predictors of remission in patients with RA also showed that low baseline disease activity was an independent predictor of remission across a variety of patient populations and treatments [19] . Despite the well-known potential benefits of achieving a target of LDA, treatment patterns were remarkably similar among patients with moderate or severe disease upon biologics initiation. The vast majority of patients were already on non-biologic DMARDS (mainly MTX) at the time of biologics initiation. Once a biologic drug was initiated, most patients persisted on that therapy. Discontinuation of the biologics occurred in <20% of patients, with most of those patients discontinuing within the first year. Switching biologic therapy was relatively uncommon in this cohort, occurring in $10% of patients per year. Although reasons for discontinuation or switching were not formally evaluated in this study, the results suggest that the majority of patients and their physicians may have been largely satisfied with the response obtained with the first biologic drug.
These data suggest that patients and physicians may be willing to accept treatment responses that are perceived as successful, even if they have not achieved the target of LDA. Therefore, modification of T2T goals may be warranted for some RA patients, for example, those with high disease activity and/or long-standing RA. For some of these patients, achievement of stringent treatment targets may be less likely or may require therapeutic interventions that have less favourable riskbenefit considerations. In clinical practice, factors that can affect the implementation of T2T principles include the required frequency of visits, extensive monitoring of disease activity and frequent switching of therapy in the case of suboptimal response [20] . These may impact patients' preferences regarding remaining on current treatments.
A strength of the current study is its use of a large, realworld RA registry, indicating good external validity of results. Limitations include that Corrona, as with all registries, is limited in terms of data collection at the times of office visits and by the frequency of reporting (36 month intervals between visits). Therefore, additional confounding factors may have remained unidentified by these analyses.
In conclusion, this real-world analysis showed that biologics are frequently prescribed to patients with both moderate and severe RA in this US-based population. Although RA patients with higher disease activity achieved a greater magnitude of response to biologic treatment compared with patients with moderate disease activity, those with moderate disease activity achieved lower levels of disease activity significantly more often than those with severe disease activity. This information may help inform clinicians and patients in choosing a therapy with consideration of T2T where achieving a target is the desired outcome.
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